Global MedTech Industry Contribution Award 2023: Recognizing Leaders Driving Innovation, Collaboration, and Sustainable Growth

In 2023, in terms of technological innovation, Siemens Healthineers' Cardiac Radioablation (CRA) system RADIATE-VT clinical trial received FDA's Investigational Device Exemption (IDE). Halcyon and Ethos radiotherapy systems were approved by FDA 510(k) and CE marking. Proton therapy system and prostate MRI-assisted diagnostic software entered NMPA’s innovation channel. Photon-counting CT NAEOTOM Alpha was approved by NMPA.

In terms of partnerships and acquisitionsIn order to promote the popularization of high-quality medical care and cultivate future medical talents, Siemens Healthineers has reached a 10-year strategic cooperation agreement with SSM Health. This is the largest regional strategic cooperation project Siemens Healthineers has ever undertaken. To meet the growing market demand for Varian radiotherapy equipment, Siemens Healthineers invested approximately 25 million euros in Germany to expand a new production building. The new production building will manufacture the electron accelerators required for the radiation sources of Siemens Healthineers' Varian radiotherapy equipment. The production building will also expand the production line for liquid metal bearings used in high-end CT and DSA.Siemens Healthineers Collaborates with Indian Startup Qure.ai to Launch AI Technology for Tuberculosis Screening Using Chest X-rays. In a Milestone Research Project, Siemens Healthineers Partners with Industrial 3D Printing and Additive Manufacturing Company Stratasys to Advance the Development of CT Phantoms.

In China, Siemens Healthineers continued to implement the "National Intelligence Innovation" localization strategy in 2023., by "promoting the localization of the entire product line," "further innovating R&D based on the needs of the Chinese market," and "advancing the upgrading of local business models," deeply participate in the construction of "Healthy China."

• The first anniversary of the release of the 5G MRI MAGNETOM Mica sees "remarkably leading" sales;

• The most advanced domestically produced PET/CT Biograph Vision Bio-Robot bionic robot has officially rolled off the production line and begun operations at the Shanghai medical device research, development, and production base.

• The world's most advanced mammography machine, MAMMOMAT Revelation, has been localized in China and put into operation at the R&D and production base in Shanghai.
  

• The first batch of mid-to-high-end Chinese-produced ultrasound ACUSON Juniper S was officially put into production and rolled off the line at the R&D and production base in Shanghai. This move marks Siemens Healthineers filling the gap in its Chinese-produced ultrasound product line.

• Partnering with Rosett and Brainlab, we bring a "one-stop" solution for intelligent orthopedic surgery, ushering in a new era of precision and efficiency with orthopedic navigation and robotic surgery systems.

Siemens Healthineers × Shenzhen Municipal Government, Sign Strategic Cooperation Memorandum!

Official Announcement of Cooperation! Siemens Healthineers Expands into Imaging Diagnostics

J&J MedTech(Johnson & Johnson's medical device business segment; Johnson & Johnson NYSE code: JNJ) has a global history that dates back to the founding of Johnson & Johnson in the United States in 1886. Johnson & Johnson originated from the production of sterile surgical sutures and dressings. Currently, it offers a wide range of products and solutions in areas such as surgery, cardiovascular and specialized solutions, orthopedics, and ophthalmology. In 1994, Johnson & Johnson Medical Technology entered the Chinese market. Currently, Johnson & Johnson Medical Technology has more than 5,000 employees in China. Its headquarters is located in Shanghai, with offices in Beijing, Guangzhou, and other cities.

In 2023, in terms of technological innovation，Multiple products in the cardiac ablation portfolio receive FDA approval,Become the first company to have a drug administration-approved atrial fibrillation ablation product that does not require fluoroscopic guidance;Elita Femtosecond Laser Approved by FDA for Market Launch;Continue to advanceDevelopment of the OTTAVA Laparoscopic Surgical Robot;The Velys orthopedic robot for total knee arthroplasty is being launched in Europe.Research on Dual-Energy (Radiofrequency + Pulsed Electric Field) Ablation Catheters Completes First Patient Cases; Subsidiary Launches Device Suitable for ChildrenAERA Eustachian Tube Balloon Dilation System.

In terms of partnerships and acquisitions, following the acquisition of an artificial heart company at the end of last yearAfter Abiomed,Johnson & JohnsonMedtronic Completes Acquisition of Laminar, a Left Atrial Appendage Closure Device Company (founded in 2019 in the U.S.), with an Upfront Payment of $400 Million (approximately 2.84 billion RMB). In collaboration with GE Healthcare, they will...OEC 3D Imaging System Promoted in Combination with Multiple DePuy Synthes Products.

Reason for Award:

In 2023, in terms of technological innovationPhilips has launched a virtual care management portfolio to provide more flexible care product solutions and corresponding services; introduced new products in the mobile C-arm series — the Zenition 10 and Zenition 30 image-guided therapy mobile C-arm systems; and unveiled the Philips CT3500, a high-throughput CT system driven by AI and designed for conventional radiology and large-scale screening program needs.

In terms of partnerships and acquisitions,Philips and Masimo Expand Collaboration to Extend Patient Monitoring Partnership into Home Telehealth Applications;Establish a new partnership with Biotronik,Expanded the range of cardiovascular devices offered to its SymphonySuite customers; sold 15% of its shares to Exor N.V., the holding company of Italy's Agnelli family; signed a two-year partnership with the World Stroke Organization (WSO), the world’s only global non-governmental organization focused on stroke, aiming to increase patient access to high-quality stroke care; received a second round of funding from the Bill & Melinda Gates Foundation, amounting to up to $44.6 million (approximately 320 million RMB), to promote the Lumify handheld ultrasound system.

In China, Philips Healthcare implemented "Smart Creation in China" in 2023, which represents the synergy between "global innovation" and "Chinese wisdom."

• SMART ICU Feifan Zhihui Critical Care Solution Tailored for Hospitals in China;

• Multiple new products achieve "Made in China," including the EPIQ CVx series AI cardiovascular dedicated ultrasound system, the Elite series full-body application ultrasound system, and the Elite W obstetrics and gynecology application ultrasound.

• Collaborating with outstanding local entrepreneurial partners in China, an open "local ecosystem" has been established, including investing in Perceive Medical to enhance the efficiency and quality of radiotherapy, upgrading the Divine Cloud intelligent diagnosis and treatment ecosystem platform in collaboration with Shenzhou Medical to provide lightweight smart imaging SaaS services, and partnering again with Shukun Technology to create the AI1024 Precision Lung Cancer Diagnosis and Treatment Center.
  

StrykerFounded in 1941, after 82 years of development, it has grown into one of the largest orthopedic and medical technology companies globally. Stryker is the world's largest producer of orthopedic products, covering various departments of surgery, including trauma orthopedics, micro implants, plastic surgery, biomaterials, endoscopes, and medical beds.

Reason for winning:

In 2023, in terms of technological innovation,Stryker released the Mako Total Knee 2.0, a robotic-arm assisted total knee replacement system, marking a new chapter for Mako SmartRobotics™; the Q Guidance System with cranial navigation software received FDA 510(k) clearance; introduced the PROstep MIS Lapidus plating system, which corrects hallux valgus deformities through minimally invasive surgery; launched the Ortho Q Guidance System, the industry's only fully automated navigation system allowing surgeons to control it easily within the sterile field; unveiled the next-generation minimally invasive surgical camera system, the 1788 Camera Platform; and introduced the first smart, connected hospital stretcher, the Prime Connect, designed to help prevent in-hospital falls.

In terms of partnerships and acquisitions,Stryker Acquires Cerus Endovascular, a Medical Device Company Focused on Designing and Developing Neurointerventional Devices for Treating Intracranial Aneurysms; Plans to Acquire SERF SAS, a French Joint Replacement Hardware Manufacturer, with Completion Scheduled for the First Quarter of 2024.

In China,StrykerIncreased localization efforts in 2023.

• The commercial launch of Mako Partial Knee Arthroplasty (PKA) this year has made the Mako SmartRobotics system the only orthopedic surgery robot currently approved by NMPA in the Chinese market for three procedures: total hip arthroplasty, total knee arthroplasty, and partial knee arthroplasty.

In 2023, in terms of technological innovation，GE Healthcare's Second-Generation Deep Learning-Based Product Sonic™️DL, CARESCAPE Canvas Patient Monitoring Platform Approved by FDA; Launched New MRI Contrast Agent, Intraoperative Ultrasound System, and Wireless Handheld Ultrasound.

In terms of partnerships and acquisitions,GE Healthcare's First Acquisition After Going Public: French Medical Technology Manufacturer IMACTIS; GE Healthcare Reaches a $760 Million, 10-Year Equipment Maintenance Agreement with Advantus Health Partners, Providing Healthcare Technology Management Services to Advantus’ Clients; GE Healthcare Enters Distribution Agreement with Johnson & Johnson’s Orthopedics Company Depuy Synthes, Combining GE Healthcare’s OEC 3D Imaging System with Depuy Synthes’ Extensive Product Portfolio to Serve More Surgeons and Patients; Collaboration with Cancer Treatment Center BAMF Health to Establish a Framework for the Development of Precision Medicine.

In China, GE Healthcare continues to implement the strategy of "comprehensive localization, boundaryless innovation, and win-win cooperation."，Improve the accessibility of precision medicine and high-quality medical resources, and contribute to the construction of "Healthy China 2030".

• GE Healthcare's Beijing factory has rolled out the "Pioneer CT" designed for China's high patient flow in emergency and outpatient settings;

• The first domestically-produced ultra-high-end quantum platform Revolution Apex Expert CT rolled off the production line at the Beijing base;

• The first domestically produced high-end dual-energy X-ray bone densitometer, Lunar iDXA, was delivered off the production line at the Beijing facility.

• The 1000th Crystal Nova Intelligent Breast Imaging System rolls off the production line and is delivered in Beijing;
  

• The cardiovascular ultrasound series achieves full production in China at the Wuxi base;

• The first batch of domestically produced nuclear medicine cyclotrons rolled off the production line at the Chengdu base, tripling the delivery speed of nuclear medicine products.

Boston Scientific（NYSE: BSX）A global cardiovascular giant, founded in 1979, with its headquarters in Massachusetts, USA.CompanyMedtronic established its China headquarters in Shanghai in 1997 and currently has branches in Beijing, Shanghai, Guangzhou, Chengdu, Hong Kong, and Taiwan. The company's core business areas cover cardiac intervention, structural heart disease, cardiac rhythm management and electrophysiology, endoscopic intervention, peripheral and tumor intervention, urology and pelvic floor health, respiratory products, and more.

• In China, the world's first approved pulsed field ablation (PFA) system has been rapidly introduced, significantly improving surgical efficiency;
• Based on the demands of the grassroots market, Medtronic independently assembled and developed the iConnect integrated surgical live streaming teaching solution, which significantly lowered the threshold for remote teaching and follow-up visits, and greatly increased the coverage and popularity of surgical procedures.
• October 9, 2023Boston Scientific Signs Agreement with Shanghai, Announcing the Official Establishment of Its First Factory in China at Lingang, Shanghai.
  
• Completed the investment in a majority stake in CinnoVas, a minimally invasive endovascular interventional company. This is the only transaction by a multinational healthcare enterprise with a Chinese listed company in the past five years. The complementary strengths of both parties will drive the development of Boston Scientific's business in China.
  

Reason for Award:

In 2023, in terms of technological innovation,BD's new Kiestra imaging application software has been approved by the FDA. This software can automatically identify bacterial growth and eliminate negative specimens, reducing human intervention; a new ultrasound device, the BD Prevue™ II Peripheral Vascular Access System, has been launched to help clinicians achieve optimal results during venous catheterization; the upgraded version of the PIVO™ needle-free blood collection device has received FDA 510(k) clearance, further contributing to...BD MedicalThe proposed "One-Needle Hospitalization" plan enhances patient experience; a brand-new ultrasound system, SiteRIte™️ 9, has been launched to improve the efficiency of vascular access devices; the MiniDraw™️ capillary fingertip blood collection system has received FDA 510(k) approval.

• PowerMe, a midline catheter product customized for the operational habits of Chinese medical staff, made its debut at the 6th CIIE, becoming a rising star in meeting the needs of medium- to long-term intravenous therapy in China's current clinical practice.
  
• Collaborated with Sinopharm Holding Medical Devices Co., Ltd., Sinopharm Health Online Co., Ltd., and Shanghai Pharmaceutical Medical Devices (Beijing) Co., Ltd. to have its StatLock products listed on the major e-commerce platforms of partners, officially expanding into new e-commerce retail channels, allowing more patients to purchase essential medical products in a timely manner.